321 related articles for article (PubMed ID: 32911689)
1. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
2. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
[TBL] [Abstract][Full Text] [Related]
3. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
5. Orbital Signaling in Graves' Orbitopathy.
Draman MS; Zhang L; Dayan C; Ludgate M
Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
[TBL] [Abstract][Full Text] [Related]
6. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
9. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA.
Zhao SX; Tsui S; Cheung A; Douglas RS; Smith TJ; Banga JP
J Endocrinol; 2011 Sep; 210(3):369-77. PubMed ID: 21715431
[TBL] [Abstract][Full Text] [Related]
10. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.
Krieger CC; Neumann S; Gershengorn MC
Pharmacol Ther; 2020 May; 209():107502. PubMed ID: 32061922
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.
Krieger CC; Neumann S; Place RF; Marcus-Samuels B; Gershengorn MC
J Clin Endocrinol Metab; 2015 Mar; 100(3):1071-7. PubMed ID: 25485727
[TBL] [Abstract][Full Text] [Related]
12. Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors.
Marcus-Samuels B; Krieger CC; Boutin A; Kahaly GJ; Neumann S; Gershengorn MC
Thyroid; 2018 May; 28(5):650-655. PubMed ID: 29631510
[TBL] [Abstract][Full Text] [Related]
13. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
[No Abstract] [Full Text] [Related]
14. TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types.
Krieger CC; Perry JD; Morgan SJ; Kahaly GJ; Gershengorn MC
Endocrinology; 2017 Oct; 158(10):3676-3683. PubMed ID: 28938449
[TBL] [Abstract][Full Text] [Related]
15. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
[TBL] [Abstract][Full Text] [Related]
16. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
17. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
Krieger CC; Boutin A; Jang D; Morgan SJ; Banga JP; Kahaly GJ; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Endocrinology; 2019 Jun; 160(6):1468-1479. PubMed ID: 31127272
[TBL] [Abstract][Full Text] [Related]
18. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
20. Autoantibodies to the IGF1 receptor in Graves' orbitopathy.
Minich WB; Dehina N; Welsink T; Schwiebert C; Morgenthaler NG; Köhrle J; Eckstein A; Schomburg L
J Clin Endocrinol Metab; 2013 Feb; 98(2):752-60. PubMed ID: 23264397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]